CD163 is required for protumoral activation of macrophages in human and murine sarcoma

Daisuke Shiraishi, Yukio Fujiwara, Hasita Horlad, Yoichi Saito, Toyohisa Iriki, Junko Tsuboki, Pan Cheng, Naomi Nakagata, Hiroshi Mizuta, Hirofumi Bekki, Yasuharu Nakashima, Yoshinao Oda, Motohiro Takeya, Yoshihiro Komohara

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Recent findings have shown the significance of CD163-positive macrophages in tumor progression, yet there have been few studies on the function of CD163 in macrophages. Here, we uncover the role of CD163 in macrophage activation using CD163-deficient mice and human samples. We detected CD163 in 62 undifferentiated pleomorphic sarcoma samples, in which a high percentage of CD163-positive macrophages was associated with decreased overall survival and higher histologic grade. We observed macrophage-induced tumor cell proliferation in cocultures of human monocyte-derived macrophages and leiomyosarcoma (TYLMS-1) and myxofibrosarcoma (NMFH-1) cell lines, which was abrogated by silencing of CD163. Tumor development of sarcoma (MCA205 and LM8) cells in CD163-deficient mice was significantly abrogated in comparison with wild-type (WT) mice. Coculture with WT peritoneal macrophages significantly increased proliferation of MCA205 cells but decreased in the presence of CD163-deficient macrophages. Production of IL6 and CXCL2 in CD163-deficient macrophages was suppressed in comparison withWTmacrophages, and overexpression of CD163 in CD163-deficient macrophages induced production of IL6 and CXCL2. Silencing of IL6 but not CXCL2 abrogated macrophageinduced proliferation ofMCA205 cells. Taken together, our results show that CD163 is involved in protumoral activation of macrophages and subsequent development and progression of tumors in mice and humans. Significance: Macrophage CD163-mediated induction of IL6 promotes tumor development and progression in murine and human malignant tumors.

Original languageEnglish
Pages (from-to)3255-3266
Number of pages12
JournalCancer Research
Volume78
Issue number12
DOIs
Publication statusPublished - Jun 15 2018

Fingerprint

Macrophage Activation
Sarcoma
Macrophages
Interleukin-6
Neoplasms
Cell Proliferation
Coculture Techniques
Leiomyosarcoma
Peritoneal Macrophages
Cell Line
Survival

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Shiraishi, D., Fujiwara, Y., Horlad, H., Saito, Y., Iriki, T., Tsuboki, J., ... Komohara, Y. (2018). CD163 is required for protumoral activation of macrophages in human and murine sarcoma. Cancer Research, 78(12), 3255-3266. https://doi.org/10.1158/0008-5472.CAN-17-2011

CD163 is required for protumoral activation of macrophages in human and murine sarcoma. / Shiraishi, Daisuke; Fujiwara, Yukio; Horlad, Hasita; Saito, Yoichi; Iriki, Toyohisa; Tsuboki, Junko; Cheng, Pan; Nakagata, Naomi; Mizuta, Hiroshi; Bekki, Hirofumi; Nakashima, Yasuharu; Oda, Yoshinao; Takeya, Motohiro; Komohara, Yoshihiro.

In: Cancer Research, Vol. 78, No. 12, 15.06.2018, p. 3255-3266.

Research output: Contribution to journalArticle

Shiraishi, D, Fujiwara, Y, Horlad, H, Saito, Y, Iriki, T, Tsuboki, J, Cheng, P, Nakagata, N, Mizuta, H, Bekki, H, Nakashima, Y, Oda, Y, Takeya, M & Komohara, Y 2018, 'CD163 is required for protumoral activation of macrophages in human and murine sarcoma', Cancer Research, vol. 78, no. 12, pp. 3255-3266. https://doi.org/10.1158/0008-5472.CAN-17-2011
Shiraishi D, Fujiwara Y, Horlad H, Saito Y, Iriki T, Tsuboki J et al. CD163 is required for protumoral activation of macrophages in human and murine sarcoma. Cancer Research. 2018 Jun 15;78(12):3255-3266. https://doi.org/10.1158/0008-5472.CAN-17-2011
Shiraishi, Daisuke ; Fujiwara, Yukio ; Horlad, Hasita ; Saito, Yoichi ; Iriki, Toyohisa ; Tsuboki, Junko ; Cheng, Pan ; Nakagata, Naomi ; Mizuta, Hiroshi ; Bekki, Hirofumi ; Nakashima, Yasuharu ; Oda, Yoshinao ; Takeya, Motohiro ; Komohara, Yoshihiro. / CD163 is required for protumoral activation of macrophages in human and murine sarcoma. In: Cancer Research. 2018 ; Vol. 78, No. 12. pp. 3255-3266.
@article{c484b63446eb4c3a93cd8eea2c85b7cf,
title = "CD163 is required for protumoral activation of macrophages in human and murine sarcoma",
abstract = "Recent findings have shown the significance of CD163-positive macrophages in tumor progression, yet there have been few studies on the function of CD163 in macrophages. Here, we uncover the role of CD163 in macrophage activation using CD163-deficient mice and human samples. We detected CD163 in 62 undifferentiated pleomorphic sarcoma samples, in which a high percentage of CD163-positive macrophages was associated with decreased overall survival and higher histologic grade. We observed macrophage-induced tumor cell proliferation in cocultures of human monocyte-derived macrophages and leiomyosarcoma (TYLMS-1) and myxofibrosarcoma (NMFH-1) cell lines, which was abrogated by silencing of CD163. Tumor development of sarcoma (MCA205 and LM8) cells in CD163-deficient mice was significantly abrogated in comparison with wild-type (WT) mice. Coculture with WT peritoneal macrophages significantly increased proliferation of MCA205 cells but decreased in the presence of CD163-deficient macrophages. Production of IL6 and CXCL2 in CD163-deficient macrophages was suppressed in comparison withWTmacrophages, and overexpression of CD163 in CD163-deficient macrophages induced production of IL6 and CXCL2. Silencing of IL6 but not CXCL2 abrogated macrophageinduced proliferation ofMCA205 cells. Taken together, our results show that CD163 is involved in protumoral activation of macrophages and subsequent development and progression of tumors in mice and humans. Significance: Macrophage CD163-mediated induction of IL6 promotes tumor development and progression in murine and human malignant tumors.",
author = "Daisuke Shiraishi and Yukio Fujiwara and Hasita Horlad and Yoichi Saito and Toyohisa Iriki and Junko Tsuboki and Pan Cheng and Naomi Nakagata and Hiroshi Mizuta and Hirofumi Bekki and Yasuharu Nakashima and Yoshinao Oda and Motohiro Takeya and Yoshihiro Komohara",
year = "2018",
month = "6",
day = "15",
doi = "10.1158/0008-5472.CAN-17-2011",
language = "English",
volume = "78",
pages = "3255--3266",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - CD163 is required for protumoral activation of macrophages in human and murine sarcoma

AU - Shiraishi, Daisuke

AU - Fujiwara, Yukio

AU - Horlad, Hasita

AU - Saito, Yoichi

AU - Iriki, Toyohisa

AU - Tsuboki, Junko

AU - Cheng, Pan

AU - Nakagata, Naomi

AU - Mizuta, Hiroshi

AU - Bekki, Hirofumi

AU - Nakashima, Yasuharu

AU - Oda, Yoshinao

AU - Takeya, Motohiro

AU - Komohara, Yoshihiro

PY - 2018/6/15

Y1 - 2018/6/15

N2 - Recent findings have shown the significance of CD163-positive macrophages in tumor progression, yet there have been few studies on the function of CD163 in macrophages. Here, we uncover the role of CD163 in macrophage activation using CD163-deficient mice and human samples. We detected CD163 in 62 undifferentiated pleomorphic sarcoma samples, in which a high percentage of CD163-positive macrophages was associated with decreased overall survival and higher histologic grade. We observed macrophage-induced tumor cell proliferation in cocultures of human monocyte-derived macrophages and leiomyosarcoma (TYLMS-1) and myxofibrosarcoma (NMFH-1) cell lines, which was abrogated by silencing of CD163. Tumor development of sarcoma (MCA205 and LM8) cells in CD163-deficient mice was significantly abrogated in comparison with wild-type (WT) mice. Coculture with WT peritoneal macrophages significantly increased proliferation of MCA205 cells but decreased in the presence of CD163-deficient macrophages. Production of IL6 and CXCL2 in CD163-deficient macrophages was suppressed in comparison withWTmacrophages, and overexpression of CD163 in CD163-deficient macrophages induced production of IL6 and CXCL2. Silencing of IL6 but not CXCL2 abrogated macrophageinduced proliferation ofMCA205 cells. Taken together, our results show that CD163 is involved in protumoral activation of macrophages and subsequent development and progression of tumors in mice and humans. Significance: Macrophage CD163-mediated induction of IL6 promotes tumor development and progression in murine and human malignant tumors.

AB - Recent findings have shown the significance of CD163-positive macrophages in tumor progression, yet there have been few studies on the function of CD163 in macrophages. Here, we uncover the role of CD163 in macrophage activation using CD163-deficient mice and human samples. We detected CD163 in 62 undifferentiated pleomorphic sarcoma samples, in which a high percentage of CD163-positive macrophages was associated with decreased overall survival and higher histologic grade. We observed macrophage-induced tumor cell proliferation in cocultures of human monocyte-derived macrophages and leiomyosarcoma (TYLMS-1) and myxofibrosarcoma (NMFH-1) cell lines, which was abrogated by silencing of CD163. Tumor development of sarcoma (MCA205 and LM8) cells in CD163-deficient mice was significantly abrogated in comparison with wild-type (WT) mice. Coculture with WT peritoneal macrophages significantly increased proliferation of MCA205 cells but decreased in the presence of CD163-deficient macrophages. Production of IL6 and CXCL2 in CD163-deficient macrophages was suppressed in comparison withWTmacrophages, and overexpression of CD163 in CD163-deficient macrophages induced production of IL6 and CXCL2. Silencing of IL6 but not CXCL2 abrogated macrophageinduced proliferation ofMCA205 cells. Taken together, our results show that CD163 is involved in protumoral activation of macrophages and subsequent development and progression of tumors in mice and humans. Significance: Macrophage CD163-mediated induction of IL6 promotes tumor development and progression in murine and human malignant tumors.

UR - http://www.scopus.com/inward/record.url?scp=85048705841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048705841&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-17-2011

DO - 10.1158/0008-5472.CAN-17-2011

M3 - Article

AN - SCOPUS:85048705841

VL - 78

SP - 3255

EP - 3266

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 12

ER -